The proposed switching of oral acyclovir from prescription to over-the-counter (OTC) status for the 5-day episodic treatment of genital herpes was considered by a consensus panel. It was concluded that self-diagnosis/misdiagnosis, misuse, and adverse drug effects were potential problems with the OTC use of acyclovir. While acyclovir reduces asymptomatic shedding of herpes simplex virus type 2, the reduction in transmission of virus potentially resulting from increased acyclovir use was felt to be of unknown extent but likely to be of benefit overall. The availability of acyclovir would likely be improved. There were differences in opinion as to whether widespread availability of acyclovir (prescription or OTC) may speed the development of viral resistance. However, all panel members felt that granting OTC status may set an undesirable precedent for the switch from prescription to OTC use of other systemically administered antiinfective agents. The effect of this precedent, in terms of accelerating development of multidrug-resistant bacteria, was a major concern of all panel members. The consensus was that the switch of acyclovir to OTC status could not be supported.
In the current era of cost-containment, more and more prodaddressed before OTC status could be granted emerged from these meetings. These issues included (1) viral resistance; (2) ucts are being switched from prescription to over-the-counter (OTC) status in the United States. Such switching may reduce transmission of herpes simplex virus (HSV) through asymptomatic shedding; (3) education (public health programs) and the overall cost of health care and empower consumers [1] . Recent switches in the United States have involved products counseling programs proposed by the manufacturer if acyclovir were made available for OTC use; (4) effect on screening for for the treatment of heartburn/indigestion, asthma/allergies, diabetes, and yeast infections.
and reporting of other sexually transmitted diseases (STDs); (5) self-diagnosis and misdiagnosis of disease; (6) misuse, inHowever, such switches are not made without serious consideration of the possible consequences. Before prescriptioncluding use in pregnancy and overdose toxicity; (7) safety, adverse-reaction reporting, and postmarketing surveillance; (8) to-OTC switches are approved, the U.S. Food and Drug Administration (FDA) specifically reviews whether consumers can accessibility (drug cost and coverage); (9) labeling; and (10) episodic vs. suppressive treatment. recognize the symptoms of the condition to be treated, the safety of the product, proposed labeling, consumers' underOn 2 February 1996 an independent ad hoc panel, composed of the present authors, met to revisit the FDA findings. The standing of such labeling, and other issues [1, 2] .
On 19 May 1994 an FDA public hearing and Antiviral/ panel heard presentations from persons in the industry and the medical community. This article summarizes the data presented Nonprescription Drugs Advisory Committees Joint Meeting were held to consider issues related to the switch from prescripand the findings of this ad hoc panel. Consideration was given to the potential OTC status of oral acyclovir only for the epition to OTC use of oral acyclovir for the treatment and suppression of genital herpes. A range of issues that needed to be sodic treatment of recurrent genital herpes, not for suppression of the disease.
The disease is thus considered to be pandemic and a prominent Resistance of HSV to acyclovir has been identified and monitored since 1973 (prior to the introduction of the drug). Over public health problem [7, 8] . It is estimated that 44 million people in the United States are infected with HSV-2, although 5,000 viral isolates have been evaluated, mainly from immunocompetent patients. In a plaque reduction assay, 0.3% of 1,139 as many as 70% do not recognize their disease [7, 9] . It is this pool of unaware individuals who probably pose the most risk isolates from untreated immunocompetent patients were found to have reduced susceptibility in vitro to acyclovir (MIC, §2 for disease transmission, as they are neither treated for nor counseled about their infection [7] . mg/mL). This was similar to the prevalence among treated individuals (0.5% of 582 isolates) [17] . The frequency of resistance in immunocompromised patients Efficacy of Acyclovir in the Treatment of Genital Herpes is higher, averaging 4.9% between 1982 and 1990 [18, 19] . The prevalence of resistant strains of virus in only those immuGenital herpes has been successfully treated with oral nocompromised patients who shed virus during therapy ranged acyclovir for many years (11 years in the United States and from 4.1% to 10.9% [18 -21] . The majority (92%) of the resis-13 in the United Kingdom). Acyclovir (200 mg five times daily tant variants are thymidine kinase -deficient and are somewhat for 5 days) has been widely used in the episodic treatment of attenuated in virulence in vivo [22] . recurrent episodes of genital herpes, where it shortens time to There are differing opinions among panel members as to healing as well as duration of viral shedding and decreases whether increased resistance to nucleoside analogs, which now new lesion formation [10 -12] . It is also effective as supinclude famciclovir and valacyclovir, would be an inevitable pressive therapy (800 mg/d in two or four doses) [10, 13 -15] outcome of use over time of this class of drugs. The increased and has been shown to significantly reduce subclinical viral availability of acyclovir may speed the development of resisshedding when used long-term [16] .
tance by several years; however, it is possible that the nucleoside analogs will be replaced by new drug classes, such as the protease inhibitors, before such resistance is widespread.
Issues for Consideration
The FDA public hearing and Antiviral/Nonprescription Asymptomatic Shedding and Transmission of HSV Drugs Advisory Committees Joint Meeting in May 1994 identified 10 broad issues for consideration with regard to OTC Unrecognized disease and asymptomatic viral shedding are acyclovir. One of these is not relevant to this commentary key factors in the transmission of infection [23, 24] . Sup-(episodic vs. suppressive treatment), as the panel considered pressive acyclovir therapy has been shown to reduce subclinical only the possible OTC availability of oral acyclovir for 5 days' viral shedding by 96% in women [16] , but it has yet to be episodic treatment. However, the panel identified another issue confirmed in clinical trials whether reduced viral shedding leads for consideration: precedence (which will be discussed later in to reduced transmission of infection. this article).
If acyclovir does lead to reduced transmission, its availability OTC and increased usage could lead to decreased transmission by allowing individuals to treat their outbreaks without visiting Viral Resistance a physician. Increased use, however, would depend on improved recognition of signs and symptoms. The panel believes Acyclovir is widely used in the therapy for many infections caused by HSV, including life-threatening diseases (neonatal that the risks of transmission will not be eliminated without patient education and counseling about barrier forms of contraherpes and herpes encephalitis) treated with the intravenous product. There is real concern that heavy use of acyclovir may ception. Such an education program is outlined below. enhance the development of resistance. Even though only the 5-day oral formulation for recurrent genital herpes is being Education considered for OTC status, it is likely that such an application would increase the overall consumption of acyclovir.
The dissemination of information to herpes sufferers or potential herpes sufferers is generally inadequate. Many physiSince HSV is an obligatory intracellular parasite, herpes virus resistance is different from bacterial resistance in that the cians do not diagnose the infection correctly [9] , or they counsel patients inadequately [24 -26] . primary concern of viral resistance is its development in the individual patient. Transmission of resistant virus from patient
In general, the public are poorly informed about genital herpes and STDs [27] . A survey of American women conducted by to patient is a theoretical concern. Acyclovir resistance is due to selection of resistant variants under selective pressure. The switch from prescription to OTC products could provide STD symptoms. an opportunity for such large-scale education programs. Pharmaceutical companies often conduct large advertising and eduMisuse, Including Use in Pregnancy, and Overdose cational campaigns for OTC products, reaching consumers via Toxicity television, magazines, and other popular media. These campaigns can focus on the disease as well as the therapy and OTC acyclovir could be misused as a suppressive therapy, even though it would be sold and packaged as a 5-day course educate not only consumers but also health care providers.
The panel was advised by Glaxo Wellcome (Research Trianof treatment. It could also be used inadvertently or deliberately during pregnancy or taken as an overdose. gle Park, NC) that the switch to OTC acyclovir would be accompanied by a major education program on STDs in general Opinions vary on the potential misuse of OTC acyclovir for suppression of genital herpes. Suppressive therapy with and genital herpes in particular. The campaign would highlight the risks of transmission and would promote safe sex practices.
acyclovir is effective and safe [32] and may also reduce disease transmission. Underdosing could promote the development of The panel agreed that such a campaign could be very useful if carried out in a medically responsible fashion, and it encourresistant virus. Nonetheless, the panel agreed that misuse of OTC acyclovir for suppressive therapy is likely to be minimal aged that such a program be implemented regardless of whether a switch to OTC acyclovir takes place.
because of the packaging and pricing of the OTC product. Nonreimbursement for OTC acyclovir is also likely to encourage patients to obtain a prescribed course of suppressive Counseling and STD Screening therapy.
The effect of use of acyclovir during pregnancy has been The OTC availability of acyclovir could lead to a decrease in counseling if patients did not consult a doctor for their monitored by a registry. Since December 1994, known outcomes were recorded for 746 exposures to the drug during first genital herpes outbreak. Decreased physician contact could promote disease transmission; on the other hand, most patients pregnancy. A total of 515 exposures occurred during the first trimester, with a 3.7% incidence of first-trimester birth defects, with genital herpes feel that their health care providers do not adequately counsel them. It is possible that a switch to OTC an incidence that does not differ from that reported for the general population [33] . Thus, although we would not encouruse of acyclovir could aid awareness of this and related STDs through accompanying education campaigns [25] . In addition, age use of acyclovir during pregnancy, we believe that its inadvertent use would be unlikely to lead to increased birth advertising may stimulate patients with suspicious lesions to seek medical care.
defects. The risk of overdose with OTC acyclovir is low. The bioavailability of oral acyclovir is only 15% -21% [34] . Patients Self-Diagnosis and Misdiagnosis of Disease with severe herpes infections receiving acyclovir (10 mg/kg iv 3 times daily) have mean plasma peaks of 91.9 mM. An Patients are usually able to recognize symptoms of recurrent active disease, as shown by clinical studies that ask patients 800-mg dose of oral acyclovir produces plasma peaks of only 6.9 mM [35, 36] . Thus, it would be difficult to overdose on with recurrent genital herpes to self-initiate treatment [11, 15, 29] . Another study showed that patients with unrecognized OTC acyclovir. In addition, the overall good safety profile of acyclovir (described below) is reassuring. disease can be taught to recognize symptoms of genital herpes [30] . Thus, the panel felt that self-diagnosis of disease by paIn addition, an OTC antiviral agent has the potential for misuse for other viral conditions such as varicella zoster or tients with previously diagnosed genital herpes was not the major issue.
even the common cold. The potential for the general population to confuse one viral infection with another is certainly a Misdiagnosis of disease is a potential problem, although it was reassuring that the Symptom Recognition and Selfconcern. Treatment Study conducted in public health clinics by Glaxo Wellcome showed that there was little confusion between syphSafety, Adverse-Reaction Reporting, and Postmarketing ilis and genital herpes on the part of the 3,000 patients interSurveillance viewed [31] . Most important, people with lesions who elected to self-initiate treatment of their lesions did not delay coming A wealth of data confirm the safety and efficacy of acyclovir [10 -16, 29, 32] . The drug has been used for over 15 years in into the clinic. There was no difference in the time from onset of symptom or sign to clinic visit between those who self-ú30 million people, has been the subject of various postmarketing surveillance studies, and has demonstrated a consistreated and those who did not. However, the sample in this / 9c48$$mr31 02-05-98 22:42:57 cida UC: CID tent absence of major adverse effects [37] . Acyclovir continues The panel believes that switching acyclovir to OTC status would encourage other applications for switching many antito be monitored on a worldwide basis and is the focus of the Resistance Monitoring Task Force, consisting of nine clinical bacterials to OTC status. While we believe that increased resistance to acyclovir will eventually occur and that OTC acyclovir virologists, including two from Glaxo Wellcome. This task force, in collaboration with the Centers for Disease Control might enhance that development, we are more concerned about the precedent it would set. At this time, the panel felt the and Prevention, is sponsoring surveillance and special interest studies in the United States and Canada on acyclovir resistance establishment of a precedent for all antimicrobials is the most compelling reason for not supporting the acyclovir switch. (E. Kern, personal communication).
Thus, the panel felt that the availability of OTC acyclovir would probably not be associated with significant safety Discussion problems, except those related to potential viral resistance, as discussed.
Although many of the issues raised about OTC acyclovir at the FDA public hearing and Antiviral/Nonprescription Drugs Advisory Committees Joint Meeting in May 1994 are no longer Accessibility: Drug Cost and Coverage of major concern, the panel believes that the switch from preThe availability of OTC acyclovir will increase accessibility scription to OTC status should not be supported for the followto the product for those patients who do not receive renewable ing reasons: OTC use would set a precedent for other antiinfecprescriptions from their physicians. It would also increase tive products, and OTC use could hasten the development of availability for those patients who are reluctant to visit physiviral resistance. cians for STDs, although such patients should be encouraged Precedence is the major issue. Microbial resistance is inevitato consult with physicians for diagnosis and counseling.
ble in the long term, and the availability of an OTC antiviral Patients who currently pay for their own prescriptions would drug would be expected to speed application for OTC antibiotpotentially benefit from a cheaper OTC product. Concern was ics and consequent resistance. Self-diagnosis, misdiagnosis, expressed that health maintenance organizations might not misuse, and safety are legitimate concerns but do not seem to cover the costs of prescription acyclovir if the product achieved be major issues at this time. OTC status, leading to problems for poorer patients. This poten-
The effect of OTC acyclovir on asymptomatic shedding and tial lack of reimbursement is disturbing, particularly as generic viral transmission is likely to be positive; effects on screening acyclovir will become available in the United States in 1998.
for and the reporting of other STDs and on counseling are less clear. However, they could be influenced positively because OTC use could improve consumer education and drug accessiLabeling bility. It would seem prudent to support such a consumer education campaign prior to approval of an OTC status for acyclovir, The panel did not consider labeling to be a major problem in order to determine its impact on the target population's because labeling can address all key issues associated with understanding of herpes and other STDs. OTC drugs. Patient-package inserts can be worded to minimize At this time, the potential benefits do not outweigh the risk misuse of OTC acyclovir, to reinforce the message that the that the setting of a precedent and the subsequent availability product should be used only when genital herpes has been of OTC antimicrobials would lead to accelerated microbial previously diagnosed, and to encourage use of condoms to resistance. prevent viral transmission. However, the fact that few patients pay attention to package inserts could be a problem.
